Aytu BioPharma Inc. (AYTU) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, AYTU scores 29 out of 100 and carries a letter grade of E, with a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are as follows:

• Fundamental Cash Engine (4 / 20): The weakest pillar, reflecting ROIC of -35% and an FCF yield of -10.06%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow relative to its valuation.
• Whale 13F Flow (5 / 20): Per the RQD rating, this pillar covers institutional accumulation and options positioning. The low score indicates weak institutional support in the source data. No holder-level detail is available in the source data to explain the score further.
• Insider Conviction (3 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is the lowest of the five pillars in absolute terms relative to its weight, signaling limited insider conviction. Specific trade records are not available in source data.
• Macro Regime Fit (6 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. The score suggests the stock does not offer a clear macro tailwind in the source framework.
• Forensic Balance Sheet (11 / 20): The strongest pillar, reflecting Altman Z 2.5, Piotroski F 5/9, and Debt/Equity 0.7. This is a relatively better reading, though it remains a mid-range result rather than a strength.

Investor implications: The composite score points to meaningful downside risk. Upside drivers in the source data are limited to the balance sheet pillar and the relatively stable 52-week range. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are all not available in source data, and the company reports negative operating and net margins. The score is educational context for evaluating the stock, not a recommendation.

Aytu BioPharma Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe specific products, customers, or revenue model. The market data shows a gross margin of 69%, indicating a high-margin product base relative to operating costs, though the product mix and customer segments are not available in source data.

Per the SEC financials, the company reported losses in all three periods, with net income of $-13.6M in FY 2025 and $-15.8M in FY 2024. Revenue was $66.4M in FY 2025, down from $107.4M in FY 2023. Per the market data, the net margin is -20.5%, the operating margin is -11.8%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9. Debt/Equity is 0.7 per the RQD rating. Cash rose to $30.0M in FY 2025 from $20.4M in FY 2024 while debt held at $10.0M.

Per the recent news section, six items are tagged to AYTU, all with a YELLOW light and MARKET WIRE impact label. The headlines are a Yahoo Finance comparison article, a TradingView estimates page, an Investing.com Form DEF 14A filing notice dated 22 October, a TradingView LSE listing page, a Yahoo Finance seasonal-returns page for RedHill Biopharma, and a Yahoo Finance quote page for Moleculin Biotech. No specific product, clinical, or financing catalyst is described in the source summaries. The proprietary signal list in the Butterfly graph is empty.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. The only sector context is the Health Care / Biotechnology: Pharmaceutical Preparations classification. An investor should watch for the proxy statement timing noted in the news wire, but no supply-chain bottleneck can be identified from the source data.

Analyst consensus is not available in source data. Per the analyst data section, no analyst records were provided. Per the holders section, no 13F, Form 4 insider, or Congressional trade records were provided, so smart-money ownership cannot be characterized beyond the RQD whale and insider pillar scores.

• What are the company's specific products, revenue sources, and customer concentration, given the revenue decline from $107.4M in FY 2023 to $66.4M in FY 2025?
• What is the cash runway, and how does the $30.0M cash balance compare with ongoing free cash outflows of $-2.2M in FY 2025?
• What drove the change in net loss between FY 2024 ($-15.8M) and FY 2025 ($-13.6M), and what is the outlook for profitability?
• What are the terms and maturity of the $10.0M debt position?
• What is the reason for the market cap of $21.5M relative to the reported balance sheet, and what does the valuation imply given the negative earnings?